Comparison of patients with invasive intraductal papillary mucinous carcinoma and invasive ductal carcinoma of the pancreas: a pathological type- and stage-matched analysis

References

• Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239(6):788–797.
   PubMed Web of Science ®Google Scholar
• Andrejevic-Blant S, Kosmahl M, Sipos B, et al. Pancreatic intraductal papillary-mucinous neoplasms: a new and evolving entity. Virchows Arch. 2007;451(5):863–869.
   PubMed Web of Science ®Google Scholar
• Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251(3):470–476.
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Shimoyama Y, et al. Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol. 2014;21(7):2444–2452.
   PubMed Web of Science ®Google Scholar
• McMillan MT, Lewis RS, Drebin JA, et al. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN). Cancer. 2016;122(4):521–533.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40(4):571–580.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T, et al. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol. 2009;100(1):13–18.
   PubMed Web of Science ®Google Scholar
• Shimada K, Sakamoto Y, Sano T, et al. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas. 2006;32(3):281–287.
   PubMed Web of Science ®Google Scholar
• Duconseil P, Périnel J, Autret A, et al. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC). Eur J Surg Oncol. 2017;43(9):1704–1710.
   PubMed Web of Science ®Google Scholar
• Yamada S, Fujii T, Hirakawa A, et al. Comparison of the survival outcomes of pancreatic cancer and intraductal papillary mucinous neoplasms. Pancreas. 2018;47(8):974–979.
   PubMed Web of Science ®Google Scholar
• Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51(5):717–722.
   PubMed Web of Science ®Google Scholar
• Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639–646.
   PubMedGoogle Scholar
• Ishida M, Egawa S, Aoki T, et al. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas. Pancreas. 2007;35(4):348–352.
   PubMed Web of Science ®Google Scholar
• Furukawa T, Klöppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch. 2005;447(5):794–799.
   PubMed Web of Science ®Google Scholar
• Fong ZV, Castillo CF. Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Visc Med.. 2015;31(1):43–46.
   Google Scholar
• Furukawa T, Hatori T, Fujita I, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60(4):509–516.
   PubMed Web of Science ®Google Scholar
• Marchegiani G, Andrianello S, Dal Borgo C, et al. Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. HPB (Oxford). 2019;21(5):596–603.
   PubMed Web of Science ®Google Scholar
• Kardon DE, Thompson LD, Przygodzki RM, et al. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Mod Pathol. 2001;14(5):443–451.
   PubMed Web of Science ®Google Scholar
• Wasif N, Bentrem DJ, Farrell JJ, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116(14):3369–3377.
   PubMed Web of Science ®Google Scholar
• Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. JAm Coll Surg. 2011;213(2):275–283.
   PubMed Web of Science ®Google Scholar
• Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011;253(5):968–974.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology [internet]. Pancreatic adenocarcinoma. Version 2. 2019 [updated 2018 Apr 9; cited 2019 May 20]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
   Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th ed. New York (NY): Wiley-Blackwell; 2009.
   Google Scholar
• Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213.
   PubMed Web of Science ®Google Scholar
• Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–557.
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–257.
   PubMed Web of Science ®Google Scholar
• Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut. 2011;60(12):1712–1720.
   PubMed Web of Science ®Google Scholar
• Adsay NV, Merati K, Basturk O, et al. Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an “intestinal” pathway of carcinogenesis in the pancreas. Am J Surg Pathol. 2004;28(7):839–848.
   PubMed Web of Science ®Google Scholar
• Yopp AC, Allen PJ. Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg. 2010;2(10):359–362.
   PubMedGoogle Scholar
• Adsay NV, Merati K, Nassar H, et al. Pathogenesis of colloid (pure mucinous) carcinoma of exocrine organs: coupling of gel-forming mucin (MUC2) production with altered cell polarity and abnormal cell-stroma interaction may be the key factor in the morphogenesis and indolent behavior of colloid carcinoma in the breast and pancreas. Am J Surg Pathol. 2003;27:571–578.
   PubMed Web of Science ®Google Scholar
• Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15(10):1087–1095.
   PubMed Web of Science ®Google Scholar
• Izumo W, Higuchi R, Furukawa T, et al. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma. Scand J Gastroenterol. 2019;54(6):780–786.
   PubMedGoogle Scholar
• Shibata K, Matsumoto T, Yada K, et al. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31(1):69–73.
   PubMed Web of Science ®Google Scholar
• Kang CM, Kim JY, Choi GH, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140(1):31–35.
   PubMed Web of Science ®Google Scholar
• Tani M, Kawai M, Miyazawa M, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg. 2009;394(2):249–253.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ohigashi H, Ishikawa O, et al. Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer. Ann Surg. 2012;255(1):95–102.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Frampton AE, Kyriakides C, et al. Locorecurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy. J Cancer Res Clin Oncol. 2012;138(6):1063–1071.
   PubMed Web of Science ®Google Scholar
• Paik KY, Choi SH, Heo JS, et al. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol. 2012;4(5):109–114.
   PubMed Web of Science ®Google Scholar
• Amin MB. American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York (NY): Springer; 2017.
   Google Scholar